Author Interviews, CDC, Infections / 10.09.2025

MedicalResearch.com Interview with: CDCKristina Betz MD, PhD Measure Development and Validation Unit Lead, NHSN Surveillance Branch Division of Healthcare Quality Promotion Centers for Disease Control and Prevention (CDC) MedicalResearch.com: Would you briefly explain what is meant by sepsis? i.e., how common is it, how serious, what are the major causes? Response: Sepsis is a life-threatening medical emergency that happens when the body’s response to an infection causes vital organs to stop working properly. Sepsis is often caused by bacteria, but it can also happen because of other infections, like viruses such as COVID-19. Sepsis is one of the main reasons people go to the hospital and can be very dangerous. In the United States, about 1.7 million adults go to the hospital each year because of sepsis. Sadly, about 350,000 of these people die in the hospital or are sent to hospice care. Even if people survive sepsis, it can cause long-lasting problems. They might have new health issues, not be able to go back to work, need to go back to the hospital, or even die later on. Source: Hospital Sepsis Program Core Elements | Sepsis | CDCWhat Is Sepsis | Sepsis Alliance
Author Interviews, Breast Cancer / 10.09.2025

MedicalResearch.com Interview with: [caption id="attachment_70616" align="alignleft" width="130"]Dr. Rima Patel Dr. Patel[/caption] Rima Patel, MD Assistant Professor The Tisch Cancer Institute, Division of Hematology/Oncology Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: Targeted treatment options for metastatic triple negative breast cancer (TNBC) are limited. TNBCs are associated with a high frequency of PTEN loss, which can lead to activation of the mTOR pathway and tumor proliferation but may be reversible with the mTOR inhibitor everolimus. A prior phase II single arm trial of carboplatin and everolimus in patients with advanced TNBC demonstrated good tolerability and preliminary efficacy. The current study is a randomized phase II trial comparing carboplatin and everolimus with carboplatin alone in patients with metastatic TNBC. We found that the combination of carboplatin and everolimus reduced the risk of progression or death by 52%. The regimen was well tolerated and provides a promising treatment option for patients with advanced TNBC.
Author Interviews, COVID -19 Coronavirus, Pediatrics, Weight Research / 09.09.2025

MedicalResearch.com Interview with: [caption id="attachment_70576" align="alignleft" width="200"]Thao-Ly Phan, MD, MPH Medical Director, Nemours Children's Health Professor of Pediatrics Thomas Jefferson University Dr. Thao Ly Phan[/caption] Thao-Ly Phan, MD, MPH Medical Director, Nemours Children's Health Professor of Pediatrics Thomas Jefferson University MedicalResearch.com: What is the background for this study? Response: The impacts of the COVID-19 pandemic have been extensively studied in adults, but there has been limited exploration of its effects on children and adolescents. While several studies have described weight gain trends in children during the pandemic, less is known about how having a diagnosis of COVID-19 contributed to these trends. Our study drew on the NIH’s National Clinical Cohort Collaborative database, a real-world database of electronic health data from over 90 institutions across the country.  We used this dataset’s unique features to compare a diverse group of more than 11,000 children diagnosed with COVID-19 to a matched cohort of children without a diagnosis of COVID-19.
Weight Research / 06.09.2025

[caption id="attachment_70560" align="aligncenter" width="500"]obesity-meds-pills Photo by Julie Viken[/caption] For decades, weight management has been a frustrating cycle for many people—dieting, exercising, seeing progress, only to experience setbacks. While lifestyle changes remain essential, science has advanced rapidly in offering medical tools to support those living with obesity and related conditions. One of the most significant breakthroughs in recent years has been the arrival of medications that target specific pathways in the body to regulate appetite, improve blood sugar, and support sustainable weight loss. The shift from injectables to pills may seem like a simple matter of convenience, but it represents a significant turning point in obesity treatment. Pills could broaden access, reduce stigma, and remove barriers that keep many people from starting or staying on therapy. For clinicians and patients alike, this is an exciting and complex moment, one that raises questions about how treatment will evolve and who will benefit most.
Anemia, Author Interviews, Hematology, JAMA, Pain Research, Pediatrics / 03.09.2025

MedicalResearch.com Interview with: [caption id="attachment_70522" align="alignleft" width="150"]Ibrahim Gwarzo, DrPH, MPH, MBBSResearch Scientist at Nemours Children’s Health
Delaware Valley, Delaware USA Dr. Gwarzo[/caption] Ibrahim Gwarzo, DrPH, MPH, MBBS Research Scientist at Nemours Children’s Health Delaware Valley, Delaware USA MedicalResearch.com: What is the background for this study? Would you briefly explain the condition of sickle cell disease and why young people frequently present to the ER with severe pain? Response: Sickle cell disease is an inherited blood disorder that affects red blood cells. It is passed down as an autosomal recessive disorder, meaning a person must inherit the defective gene from both parents to have the disease. The condition primarily impacts hemoglobin, the protein responsible for carrying oxygen in red blood cells, which leads to changes in the shape and stability of these cells. The complications associated with the disease, including recurrent and severe pain episodes, are a direct result of these changes. These pain episodes are debilitating and unpredictable, resulting in frequent emergency department visits where they are typically treated with pain medications, including opioids. It is estimated that around 100,000 people in the United States have sickle cell disease, with about 40,000 being children. The disease has a significant prevalence in the Afro-Latino population.
Diabetes / 29.08.2025

MedicalResearch.com Interview with: [caption id="attachment_70452" align="alignleft" width="150"]Dr. Simon Berry MRCP, MbChBClinical Research Fellow in Diabetes School of Medicine and Population Health Sheffield Teaching Hospitals NHS Foundation Trust University of Sheffield Sheffield, UK Dr. Berry[/caption] Dr. Simon Berry MRCP, MbChB Clinical Research Fellow in Diabetes School of Medicine and Population Health Sheffield Teaching Hospitals NHS Foundation Trust University of Sheffield Sheffield, UK   MedicalResearch.com: What is the background for this study? What are the main findings? Response: Obesity is an increasing problem in people with type 1 diabetes, augmenting cardiovascular risk and leading to issues with insulin resistance, which make it harder to match insulin injections to carbohydrate intake. Tirzepatide is licensed for the management of type 2 diabetes and obesity. Our study looked at people with type 1 diabetes who had been prescribed tirzepatide off-license. It found that after starting tirzepatide, there was significant weight loss, improvements in glucose levels (HbA1c and time in range on continuous glucose monitoring) and reductions in insulin requirements. Side effects such as nausea and vomiting were common but generally tolerated and importantly, there was no increase in the frequency of low blood glucose levels (hypoglycaemia) or any cases of pancreatitis.

AI and HealthCare, Author Interviews, Cannabis, Pharmacology, Technology / 28.08.2025

[caption id="attachment_70470" align="alignleft" width="150"]Duncan Dobbins, PharmD, MHIGeisinger College of Health Sciences Scranton, Pennsylvania Dr. Dobbins, PharmD[/caption] MedicalResearch.com Interview with: Duncan Dobbins, PharmD, MHI Geisinger College of Health Sciences Scranton, Pennsylvania MedicalResearch.com: What prompted this commentary, and what did you find? Response: In theory, there could be a drug interaction between immunotherapy and medical cannabis. A small (N=102) observational report from Israel appeared to find that immunotherapies worked much less well in cancer patients who also used medical cannabis.1 However, a follow up report2 took about two weeks and involved manually rechecking the math and data-analysis. Several discrepancies emerged between the methods and results. Two-tailed tests were listed in the methods yet one-tailed p values appeared in the results. Arithmetic errors, some traceable to unconventional “floor” rounding, affected key percentages. Multiple p values in Table 1 (21 out of 22) could not be reproduced with the stated tests. Finally, smoking status, a key confound, was not reported. Taken together, these issues complicate interpretation and highlight how small computational slips can cascade into larger inferential uncertainty. For this follow-up report, I was asked, “Do you think AI could have double checked this math?”
Accidents & Violence, Legal-Malpractice / 26.08.2025

catastrophic-injuries A catastrophic injury is a serious injury that changes a person’s life forever. These injuries often cause permanent disabilities, limit a person’s ability to work, and require long-term medical care. They can result from accidents at work, vehicle crashes, or dangerous conditions in public places. In a busy city like Oklahoma City, where major highways like I-35, I-40, and I-44 intersect and industries such as education, healthcare, and retail bring in thousands of workers and visitors every day, the risk of serious accidents is always present. When these accidents lead to catastrophic injuries, victims often face overwhelming medical and financial challenges. An Oklahoma City catastrophic injury lawyer can help victims understand their rights, gather evidence, and seek fair compensation for both current and future needs. Without proper legal help, many people miss out on the resources they need for recovery.
Author Interviews, Mental Health Research / 25.08.2025

[caption id="attachment_70390" align="alignleft" width="142"]Maria Y. Tian, MBSDepartment of Medical Education
Geisinger College of Health Sciences
Scranton, Pennsylvania Maria Tan[/caption] MedicalResearch.com: Maria Y. Tian, MBS Department of Medical Education Geisinger College of Health Sciences Scranton, Pennsylvania MedicalResearch.com: What is the background for this study? Response: Schizophrenia-spectrum disorders are severe, disabling conditions that are associated with substantial economic burden. Approximately one-third of patients have treatment-resistant schizophrenia, which clozapine is the only evidence-based therapy for. Clozapine also provides unique benefits, including reduced suicide risk, aggression, and all-cause mortality. Despite this, it has historically been underutilized due to concerns over adverse effects, required blood monitoring, patient adherence, and limited clinician training. Previous research in Medicaid populations had demonstrated marked state-level variation in use, but little was known about prescribing trends in the U.S. Medicare system, which covers nearly half of individuals with schizophrenia. This study analyzed Medicare Part D data from 2015–2020 to assess national and regional trends in clozapine prescribing and to identify states with significantly different prescribing patterns.

Author Interviews, Infections / 24.08.2025

MedicalResearch.com Interview with: [caption id="attachment_70374" align="alignleft" width="200"]Dr. Neta Shlezinger Ph.D.Koret School of Veterinary Medicine Hebrew University Dr. Neta Shlezinger | Credit: Zuckerman Faculty Scholar Zuckerman Institute[/caption] Dr. Neta Shlezinger Ph.D. Koret School of Veterinary Medicine Hebrew University with  Dr. Marina Campos Rocha Ph.D., Dr. Vanda Lerer, PhD., and student John Adeoye MedicalResearch.com: What is the background for this study?  What are the main findings? Response:  Fungal pathogens pose a growing threat to global health, particularly for immunocompromised individuals. Today, we appreciate that fungi kill more people each year than malaria and tuberculosis combinedAspergillus fumigatus stands out as a leading cause of invasive fungal infections, responsible for approximately 65% of all invasive mold infections in humans. These infections carry mortality rates that can exceed 50%, even with standard care. Treatment options remain limited: only a handful of antifungal drug classes are clinically available, and resistance is increasingly reported to all of them. As a result, the search for novel therapeutic strategies is now focused on fungal-specific virulence factors — targets that are essential for fungal survival and pathogenicity in the host but are absent in humans. Meanwhile, research in recent years has revealed that many fungi harbor viruses. These mycoviruses are surprisingly prevalent, but their impact on fungal physiology and, crucially, on fungal pathogenicity in humans has remained largely unexplored. Our study set out to fill this gap by examining a double-stranded RNA virus, Aspergillus fumigatus polymycovirus 1 (AfuPmV-1M), that naturally infects A. fumigatus. We found that this virus isn’t just a silent passenger — it’s wired into key fungal stress response pathways, helping the fungus survive heat stress, evade oxidative damage, and persist in the lung environment. In other words, it acts like a backseat driver — quietly steering the fungus toward enhanced survival and virulence. When we “cured” the fungus of its virus, it produced fewer spores, made less melanin, became more vulnerable to stress, and caused milder infections in mice. Seeing this, we explored a therapeutic twist: fight the virus to clear the fungus. We treated infected mice with antiviral compounds during fungal infection and observed reduced mycovirus levels and improved survival. Together, these results suggest that mycoviruses can be overlooked drivers of fungal disease — and targeting them may represent a novel, host-sparing therapeutic strategy.
Author Interviews, Genetic Research, Heart Disease / 14.08.2025

MedicalResearch.com Interview with: [caption id="attachment_70301" align="alignleft" width="92"]Takeshi Tsuda, MDSenior Pediatric Cardiologist Nemours Cardiac Center Nemours Children’s Health Delaware Dr. Tsuda[/caption] Takeshi Tsuda, MD Senior Pediatric Cardiologist Nemours Cardiac Center Nemours Children’s Health Delaware MedicalResearch.com: What is the background for this study?  Would you briefly explain the condition of Duchenne Muscular Dystrophy? Response: Duchenne muscular dystrophy (DMD) is a genetic muscle disorder causing progressive muscle weakness and wasting, resulting in severe disability during childhood due to absence of dystrophin protein in the muscle cells. Cardiac disease (cardiomyopathy) also develops during early adolescence, potentially leading to heart failure. Because of its insidious progression, the onset of DMD cardiomyopathy is not clearly identified. Early treatment is essential for better outcomes, but the recognition of the preclinical stages of disease is challenging. MedicalResearch.com: Is Unrelieved Wall Stress a commonly recognized echocardiogram finding? Response: Duchenne muscular dystrophy cardiomyopathy is a unique myocardial abnormality caused by the absence of dystrophin, which serves not only as a cytoskeletal protein to maintain cellular integrity but also as a mechano-sensor to adjust wall stress to normalize myocardial oxygen demand. Dystrophin deficiency results in lack of these functions, resulting in rapid myocyte death without compensatory response to normalize wall stress. By our methods, we are able to identify the unrelieved wall stress (increase in iWS) as an early sign of DMD cardiomyopathy before visible ventricular dysfunction prevails, not by the known routine approach.
Weight Research / 07.08.2025

MedicalResearch.com Interview with: [caption id="attachment_70205" align="alignleft" width="125"]Shannon D. DonofryBehavioral Scientist B.A.Sc. in psychology/neuroscience University of Pittsburgh-Pittsburgh Campus; Ph.D, University of Pittsburgh-Pittsburgh Campus Dr. Donofry[/caption] Shannon D. Donofry Ph.D. Behavioral Scientist B.A.Sc. in psychology/neuroscience University of Pittsburgh-Pittsburgh Campus; Ph.D, University of Pittsburgh-Pittsburgh Campus   [caption id="attachment_70207" align="alignleft" width="125"]Katherine M. Rancaño, Ph.DAssociate Policy Researcher RAND Dr. Rancaño[/caption] Katherine M. Rancaño, Ph.D Associate Policy Researcher RAND   MedicalResearch.com: What is the background for this study? Response: GLP-1 medications were first used to help people with diabetes manage their blood sugar. Lately, they’ve become popular for helping people lose weight, too. Because of this, a lot more people have started using them. In our study, we asked over 8,000 adults from across the country about their use of GLP-1 medications and any side effects they had.
Author Interviews, Geriatrics, JAMA, Pharmacology / 05.08.2025

MedicalResearch.com Interview with: [caption id="attachment_70179" align="alignleft" width="220"]Emily G. McDonald MD MSc (Epi) FRCPCScientist | Research Institute of the McGill University Health Centre Associate Professor of Medicine | General Internal Medicine | McGill University Health Centre Associate Chair of Quality and Safety | Department of Medicine | McGill University Director | Canadian Medication Appropriateness and Deprescribing Network Centre for Outcomes Research and Evaluation (CORE) Montreal, QC Dr. McDonald[/caption] Emily G. McDonald MD MSc (Epi) FRCPC Scientist | Research Institute of the McGill University Health Centre Associate Professor of Medicine | General Internal Medicine | McGill University Health Centre Associate Chair of Quality and Safety | Department of Medicine | McGill University Director | Canadian Medication Appropriateness and Deprescribing Network Centre for Outcomes Research and Evaluation (CORE) Montreal, QC https://www.medsafer.org/ https://www.deprescribingnetwork.ca/   MedicalResearch.com: What is the background for this study? What are the main findings? Response: Polypharmacy (taking multiple medications) is common among older adults and can lead to serious side effects like memory problems, falls, fractures, and hospitalization. Deprescribing (the process of stopping some medications that may no longer be beneficial or where the harms outweigh the benefits) is a great solution. This study found that an electronic tool to support prescribers increased deprescribing more than 3 times compared to usual care without the software support.
Dermatology, Vitamin C / 04.08.2025

MedicalResearch.com Interview with: Dr. Akihito Ishigami Ph.D. Vice President of the Division of Biology and Medical Sciences Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan MedicalResearch.com: What is the background for this study? Response: Keratinocyte differentiation is a highly regulated process essential for the stratified structure of the epidermis and must be balanced with cell proliferation. While Vitamin C (VC) is a known cofactor for DNA demethylation enzymes, its specific role in DNA demethylation during keratinocyte differentiation was unclear. This study aimed to evaluate VC's role in the epigenetic regulation of epidermal proliferation and differentiation using a human epidermal equivalent model to understand how VC affects gene expression via DNA demethylation changes.
Addiction, Cannabis, Pediatrics / 02.08.2025

[caption id="attachment_70143" align="alignleft" width="200"]Dr-Michael-S-Dunbar Dr. Dunbar[/caption] MedicalResearch.com Interview with: Michael S. Dunbar, PhD Senior Behavioral Scientist RAND MedicalResearch.com: What is the background for this study? Response: Cannabis products are way stronger, or more potent, today than they were 20 years ago. In the past few decades, average levels of THC (i.e., the main substance in cannabis that leads to feeling high) in cannabis products have risen dramatically. With cannabis becoming increasingly accessible in places like the U.S., health officials have raised questions about how higher-potency products might be associated with problematic cannabis use and related harms, including cannabis use disorder. This is especially important for at-risk groups like young adults, who tend to use cannabis at higher rates than other age groups. One perspective is that people may use high-potency products less frequently and/or in lower amounts (i.e., “titrate”), which could mitigate some potential risks. Alternatively, if people use higher-potency products more frequently or heavily, it may increase potential for harm. In this study, we looked at how use of higher-potency cannabis flower correlated with use behavior and symptoms of problematic cannabis use in a sample of young adults.
Geriatrics, Pharmacology / 29.07.2025

As people age, managing medications often becomes more complicated. With multiple chronic conditions, evolving health needs, and varying prescription instructions, seniors can easily become overwhelmed by their routines. While pill organizers and reminder apps are helpful, truly effective medication management requires a broader understanding of the physical and emotional factors that come with aging. Improper medication use can lead to serious consequences, including missed doses, interactions, and unwanted side effects. However, when the right support system is in place, these routines can be made safer, easier to follow, and more aligned with the senior’s overall well-being. A person-centered approach is essential. Medication plans should reflect a senior’s individual habits, preferences, and lifestyle rather than focusing solely on a list of prescriptions. One individual may manage their medications confidently but still forget an afternoon dose due to a shifting appetite or nap schedule. Another may feel anxious when prescriptions change, especially if past experiences with side effects have left them cautious. Addressing these personal dynamics allows caregivers and preventative healthcare providers to offer support that fits real-life situations.
Breast Cancer / 29.07.2025

Each October brings a wave of pink ribbons and powerful reminders about the importance of breast cancer awareness. Campaigns promoting early detection through mammograms have undoubtedly saved lives, but beneath the surface, many individuals still quietly face obstacles that prevent them from getting screened. These barriers are often overlooked, yet they carry serious consequences. Barriers Beyond the Calendar Scheduling a mammogram may seem simple, but the reality is often much more complex. For many, there are hidden layers of stress, confusion, and logistical difficulty. Language differences, cultural norms, limited transportation, or lack of childcare can all stand in the way of following through with a screening. People new to the healthcare system may not even know how to begin the process or where to go. Emotional and mental health challenges also play a significant role. Anxiety about medical settings, concerns over body image, or past negative healthcare experiences can discourage someone from seeking help. For some, the fear of a potential diagnosis becomes a powerful reason to avoid screenings altogether. These personal and psychological hurdles are just as important to acknowledge as physical and financial limitations.
Author Interviews, Pediatrics / 29.07.2025

Medical visits can be stressful for children and their families. Bright lights, unfamiliar equipment, and long wait times often contribute to feelings of fear or anxiety. In pediatric healthcare environments, thoughtful design can play a powerful role in easing those emotions and making care experiences more positive. One effective approach is to integrate play into waiting and treatment areas. Child-friendly features like interactive walls, hands-on games, or themed décor help create a sense of comfort. These playful elements serve as distractions, giving children something to focus on while they wait or recover. In patient rooms, cheerful artwork or access to natural light can create a more peaceful atmosphere and support emotional well-being.
Cannabis / 28.07.2025

Editor's note: Discuss your use of THC, Cannabis or CBD products with your health care provider.  Dosing of CBD is variable, especially since it is not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. [caption id="attachment_70032" align="aligncenter" width="500"]Cannabinoids and Endocannabinoids Freepik image[/caption] The human body is a complex network of systems working harmoniously to maintain balance and health. One of the lesser-known but critically important systems is the endocannabinoid system (ECS). This intricate system plays a vital role in regulating a variety of physiological processes, including mood, pain sensation, appetite, and immune response. Central to the ECS are cannabinoids: both those produced naturally within the body and those introduced from external sources like cannabis. Understanding how cannabinoids interact with the endocannabinoid system is key to unlocking their therapeutic potential and appreciating their impact on human health.

What is the Endocannabinoid System?

The endocannabinoid system is a biological network found in all vertebrates, including humans. It consists primarily of three components:
  • Endocannabinoids
  • Cannabinoid receptors
  • Enzymes that synthesize and degrade endocannabinoids
Discovered in the early 1990s, the ECS has since been recognized as a crucial regulator of homeostasis—the body’s internal balance. Endocannabinoids are naturally occurring lipid-based neurotransmitters, the most well-known being anandamide and 2-arachidonoylglycerol (2-AG). These molecules bind to cannabinoid receptors, which are located throughout the body, including the brain, immune cells, organs, and connective tissues. The two primary receptors are CB1 and CB2, each with distinct functions and locations. CB1 receptors are predominantly found in the central nervous system, influencing memory, pain, and motor control, while CB2 receptors are mostly present in the peripheral nervous system and immune cells, modulating inflammation and immune responses.
Fundraising / 28.07.2025

[caption id="attachment_70026" align="aligncenter" width="500"]Creative Fundraising Ideas Photo by RDNE Stock project[/caption] Fundraising doesn't have to be predictable or boring. In fact, the most impactful campaigns often come from thinking outside the box. Whether you're raising money for a charity close to your heart, a local cause, or a global initiative, injecting some creativity into your efforts fundraising ideas that generate funds and inspire community involvement.

1. Host a Themed Challenge

One of the most engaging ways to raise money is by organizing a themed challenge. Think beyond the typical 5K run or bake sale—what about a 24-hour dance-a-thon, a virtual escape room tournament, or a costume walkathon? These events tap into people's love for fun and friendly competition, making it easier to rally donations. Make it even more effective by encouraging participants to collect sponsorships for completing their challenges. You can use online platforms to track progress and build a community around the event.
Addiction, addiction-treatment, Author Interviews / 27.07.2025

MedicalResearch.com Interview with: [caption id="attachment_70015" align="alignleft" width="152"]Prof. Yonatan M. Kupchik PhD andLiran Levi, PhD student Faculty of Medicine at Hebrew University Prof. Kupchik[/caption] Prof. Yonatan M. Kupchik PhD and [caption id="attachment_70017" align="alignleft" width="138"]Liran Levi L. Levi[/caption] Liran Levi, PhD student Faculty of Medicine at Hebrew University MedicalResearch.com: What is the background for this study? Response: Motivated behavior is driven by a group of brain regions called collectively the reward system. This neural system is at the heart of every decision we make about our actions - it integrates information about the world and decides whether to perform a behavior or not based on the predicted reward/benefit. The key molecule in this process is dopamine - whenever we perform a behavior that provides a reward dopamine is released in the reward system and reinforces this behavior. Drugs of abuse exploit this system - they cause abnormally high levels of dopamine, and thus force the reward system to seek drugs constantly, even after prolonged withdrawal. From a neurobiological perspective, that is how we view substance dependence - the reward system drives people to seek for the reward.
Aging, Exercise - Fitness / 25.07.2025

MedicalResearch.com Interview with: [caption id="attachment_69623" align="alignleft" width="180"]Ding Ding (Melody), Ph.D., MPHProfessor of Public Health/NHMRC Emerging Leader Fellow Prevention Research Collaboration Sydney School of Public Health Faculty of Medicine and Health The University of Sydney Prof. Ding[/caption] Ding Ding (Melody), Ph.D., MPH Professor of Public Health/NHMRC Emerging Leader Fellow Prevention Research Collaboration Sydney School of Public Health Faculty of Medicine and Health The University of Sydney MedicalResearch.com: What is the background for this study? Response: While we already know physical activity benefits health, public guidelines focus on total minutes of moderate-to-vigorous activity per week, usually 150 to 300 minutes. However, many people track their activity by steps, a simple and accessible metric, but the popular 10,000-steps-a-day goal isn’t actually based on solid evidence. Our review sought to clarify how many steps per day are linked to meaningful health benefits.
Author Interviews, Environmental Risks, NYU/NYMC / 23.07.2025

MedicalResearch.com Interview with: [caption id="attachment_69606" align="alignleft" width="225"]Dr. George D. Thurston ScD Professor of Medicine and Population Health Director of the Program in Exposure Assessment and Human Health Effects NYU Grossman School of Medicine Division of Environmental Medicine NYC, NY 10010   Prof. Thurston[/caption] Dr. George D. Thurston Professor of Medicine and Population Health NYU Grossman School of Medicine Division of Environmental Medicine NYC, NY 10010   USA MedicalResearch.com: What is the background for this study? What were some of the chemicals released by the coal-coking plant? Response: Pittsburgh has a long history as the nation's principal source of bituminous coal production and home to iron and coke industries since the late 19th century, and is also known as one of the cities with the highest levels of air pollution and most air-pollution related deaths in the US, to date. The Shenango, Inc Coke Plant was one of the significant industrial emission sources in the area before its closure in January 2016. Coal-coking plants like the Shenango plant utilizes a destructive heated distillation process called pyrolysis to volatilize and drive the impurities out of coal and produce coke, a purer product with higher carbon content for use in iron and steel production. From this process, coke plant operations are known to generate high emissions of complex air pollution mixtures into the ambient air, including particulate matter (PM), sulfur dioxide (SO2), nitrogen oxides (NOx), polycyclic organic matter (POMs), volatile compounds (VOCs), and volatilized trace metals such as arsenic, nickel, selenium, lead, and cobalt. Our study examines the changes in respiratory health in the community residing near the Shenango Coke Plant before vs. after its closure,  providing a direct quantification of the health benefits of such fossil-fuel-related air pollution reductions. 
Addiction, addiction-treatment, Opiods / 23.07.2025

[caption id="attachment_69662" align="alignleft" width="150"]Maria Gikoska, MBSGeisinger College of Health Sciences Scranton, PA 18509 Maria Gikoska[/caption] MedicalResearch.com Interview with: Maria Gikoska, MBS Geisinger College of Health Sciences Scranton, PA 18509 MedicalResearch.com: What is the background for this study? Response: Opioid use disorder (OUD) is a chronic condition that continues to substantially impact public health in the United States (U.S.), with approximately 5.7 million people affected in 2023. Buprenorphine, a partial mu-opioid receptor agonist, is widely used for treating OUD due to its safety profile, high treatment retention, and effectiveness in reducing opioid-related mortality. Since its approval in 2002, its use has increased, though not uniformly across states. Factors such as the now- eliminated X-waiver, telemedicine expansions during the COVID-19 pandemic, and differing state level policies have influenced buprenorphine access. The study sought to evaluate national and state-level pattern in buprenorphine distribution from 2019-2023 to understand disparities and inform public health interventions.
Aging, Author Interviews, Genetic Research / 15.07.2025

The study was done by a team of researchers at the The Hebrew University-Hadassah Medical Schoolled by Bracha Ochana and Daniel Nudelman, under the supervision of Prof. Tommy Kaplan, Prof. Yuval Dor and Prof. Ruth Shemer. [caption id="attachment_69520" align="alignleft" width="150"]Prof. Tommy Kaplan Prof. Tommy Kaplan[/caption] MedicalResearch.com: What is the background for this study? Response: DNA methylation is a key epigenetic modification that annotates the human genome. It is established during development and cellular differentiation, and is associated with maintenance of cell type identity and control of gene expression. Nonetheless, few regions in the human genome change with age and serves as a powerful biomarker for estimating chronological and biological age. However, most current epigenetic clocks rely on average methylation at individual CpG sites using array-based data, which overlook complex regional patterns across neighboring methylation sites. This study aimed to understand how time and age are encoded at the molecular and cellular level, and to develop a highly accurate age predictor, based on regional methylation dynamics. [caption id="attachment_69521" align="alignleft" width="150"]Prof. Ruth Shemer Prof. Ruth Shemer[/caption] MedicalResearch.com: What types of cells were used in the study, ie keratinocytes, muscle cells etc? Response: The primary tissue used in this study was peripheral blood from over 300 healthy human donors (18-78 years old). To further understand how the methylation changes are associated with changes in blood cell composition, we also sorted immune cell types including neutrophils, monocytes, B cells, and T cells. For forensics applications, we also tested the clock on urine and saliva samples.     [caption id="attachment_69522" align="alignleft" width="125"]Prof. Yuval Dor Prof. Yuval Dor[/caption] MedicalResearch.com: Does this study relate at all to telomere length?Response: Response: No, this study does not investigate or reference telomere length. It focuses entirely on DNA methylation changes at few genomics regions, each covering multiple clustered DNA methylation sites, where methylation changes are indicative of chronological age, independently of telomere biology.   MedicalResearch.com: What are the main findings? Response:  - A single-molecule analysis using DNA sequencing, revealed that age-related methylation changes often occur regionally across multiple neighboring methylation sites, either in a stochastic or in a block-like manner. - A deep neural network model, called MAgeNet, was trained on methylation patterns from two specific genomic loci (ELOVL2 and C1orf132) and was able to predict chronological age (of held-out test-set donors) at a median accuracy of 1.36 years (for individuals under 50). - These predictions are robust to sex, smoking, BMI, and biological age markers, and accurate even from as few as 50 cells or at low-depth sequencing. - Longitudinal sampling of healthy donors at the age of 32 and 42, shows that early deviations from predicted age persist over time, suggesting that as we age, methylation changes faithfully encode the passage of time.
Author Interviews, Biomarkers, Lung Cancer / 12.07.2025

MedicalResearch.com Interview with: [caption id="attachment_69504" align="alignleft" width="200"]Gabriele Campanella, PhDAssistant Professor
Windreich Department of Artificial Intelligence and Human Health
Icahn School of Medicine at Mount Sinai Dr. Campanella[/caption] Gabriele Campanella, PhD Assistant Professor Windreich Department of Artificial Intelligence and Human Health Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Response: Lung cancer is the most lethal cancer in the US. Lung adenocarcinoma (LUAD) is the most common form of lung cancer with an incidence of over 100k per year in the US. EGFR mutations are common driver mutations in LUAD, and importantly, these mutations can be targeted by TKI therapy, which has high response rates. Because of this, EGFR testing via NGS (Next Generation Sequencing) is considered mandatory by guidelines for any LUAD diagnosis. In high-resource settings, rapid EGFR testing is done while waiting for confirmation via NGS. This is because NGS takes about 2 weeks on average, while the rapid testing has a median TAT of 2 days. Early treatment decisions could be made based on the rapid test results. Rapid tests have some important drawbacks, most notably, it exhausts tissue. In lung cancer, tissue is scarce in the first place, and up to 25% of cases, after rapid testing there is not enough tissue for NGS. In those circumstances, patients have to be biopsied again, which adds unnecessary risk for the patient. Even worse, in some cases, the NGS is never done. A non-tissue-exhaustive computational biomarker could be used instead of the tissue-based rapid test.
Accidents & Violence, Legal-Malpractice / 08.07.2025

Car Accidents and Personal Injury: What You Should Know Car accidents can happen in the blink of an eye, leaving you feeling shocked, confused, and unsure of what to do next. Whether it's a minor fender-bender or a serious crash, injuries can have long-term effects on your health, finances, and overall well-being. Understanding your rights and knowing how to handle a personal injury claim can make all the difference in getting the compensation you deserve. If you or a loved one has been injured in a car accident, don't wait. Learn how to protect yourself and take the right steps toward recovery today!

Understanding Your Legal Rights

Knowing your legal rights after a car accident is important. You have the right to seek compensation if someone else caused your injuries. This can cover medical bills, lost wages, and pain and suffering. Insurance companies may try to settle for less than you deserve. You do not have to accept their first offer. A personal injury lawyer can help you understand your options. There are time limits for filing a claim, so acting quickly is important. Protecting your rights can make a big difference in your recovery and financial future.